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Introduction  
The antimalarial drug hydroxychloroquine (HCQ), widely available to treat autoimmune 
diseases, has been suggested to be a therapeutic tool in the management of COVID-19 
patients and reported to be significantly associated with viral load reduction/disappearance 
(1). However, experimental data in relation to the anti-thrombotic and anti-inflammatory 
mediated effects of HCQ are still limited.  
Methods  
For the in vivo study, twenty-five PCR-confirmed COVID-19 non-critically ill patients (mean 
age 61.3± 4.4; 16 male; 22 with upper respiratory tract infection symptoms; 17 with CT-scan 
confirmed lower respiratory tract infection symptoms; 12 with gastrointestinal 
manifestations, all with T >37,5°C and Sa02 >93% at admission) were included in a single 
arm protocol from early March to April 7, 2020, to receive 400 mg of HCQ daily as an add-on 
therapy to antiviral agents (lopinavir/ritonavir 200/50 mg, bid). Interleukin-6 (IL-6, Elecsys® 
IL-6 - Diagnostics Roche) levels were assessed before starting HCQ and at day 3 and 7.  
In vitro experiments were designed to confirm the clinical findings. Changes in the levels of 
IL-6 were investigated in the supernatants of human umbilical vein endothelial cells 
(HUVEC) and human umbilical arterial endothelial cells (HUAEC) induced by pro-
inflammatory stimulation with thrombin-activated platelets and tumor necrosis factor-α 
(TNF-α) as previously described (3,4). In brief, HUVEC and HUAEC were pre-incubated for 24 
h with HCQ (concentrations 500, 1000, 2000 ng/ml), corresponding to the range of reported 
serum levels under HCQ therapy with 400 mg/daily) (2) and then stimulated for 1 hour with 
TNF-α in direct contact with thrombin activated platelets to mimic a pro-inflammatory and 
pro-thrombotic condition. After incubation the expression of urokinase plasminogen 
activator receptor (uPAR) and Intercellular Adhesion Molecule 1 (ICAM-1) on endothelial 
cells were measured by flow cytometry. This study was conducted in accordance with the 
Helsinki Declaration and the protocol was approved by the local committee for off-label 
drug use. 
Results  
In the in vivo experiments, we observed a significant reduction in the IL-6 levels after the 
beginning of treatment with HCQ (IL-6 baseline media [SEM] 597.7 ± 495.3 pg/ml;  day 3:  
369.7 ± 275.1 pg/ml;  day 7:  114.3 ± 57.5 pg/ml, p < 0.05) (Figure 1). Ferritin levels also 
showed a trend in reduction, albeit not statistically significant (baseline media [SEM] 1181.5 
± 244.4 ng/ml; time 1: 1190.1±187.7 ng/ml; time 3: 907.0 ± 216.6 ng/ml, p=0.1898). In vivo 
results were paralleled by the in vitro experiments.  The in vitro experiments were 
performed on HCQ pre-incubated HUAECs under inflammatory conditions  and showed a 
dose dependent IL-6 reduction (as already observed in HUVEC, data not shown) (Figure 1.B) 
as well as a reduction of expression of uPAR and ICAM-1 (Figure 2). 
Discussion   
Very recently Gautret et al. (1) observed that HCQ was associated with an early (three to six 
days) clearing viral nasopharyngeal carriage of COVID-19 patients. A significant difference 
was found between HCQ-treated patients and controls starting even on day 3 post-
inclusion. These clinical results were in line with the in vitro findings by Yao et al. (5), 
demonstrating that both chloroquine and HCQ inhibit COVID19 in vitro, with HCQ found to 
be more potent than chloroquine. When analysing predictors of mortality in a recent 
retrospective multicentre study of 150 confirmed COVID-19 cases in Wuhan, China, Ruan 
and colleagues found elevated IL-6 levels, among inflammatory serological markers, were 
predictors of a fatal outcome, suggesting that mortality might be due to virally driven 
“cytokine storm syndrome” (6). Our observation suggests that the use of HCQ in non-
critically ill patients might represent a pragmatic approach to reduce the hyperinflammation 
and the pro-thrombotic status, with consequent positive impact on prognosis. The lack of 
control groups, small sample size and the use of concomitant antiviral therapy may limit the 
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Figure 1. Colum bar graph showing a significant reduction in the IL-6 levels  after the 
beginning of treatment with HCQ (baseline; day 3; day 7). 
Figure 2. PANEL A. Concentrations of IL-6 in the supernatants of thrombin-
prestimulated platelets enhanced human umbilical arterial endothelial cells (HUAEC) 
assed by enzyme linked immunosorbent assay for soluble IL-6 with and without 24 h 
pre-incubation with 500/1000/2000 ng/ml HCQ. PANEL B. Expression of ICAM-1 
(PANEL B) and uPAR (PANEL C) on HUAEC with and without 24 h pre-incubation with 
500/1000/2000 ng/ml HCQ expressed by mean fluorescence intensity arbitrary unit 
 
PLT = platelets; TH= thrombin; TNFalpha = tumor necrosis factor alpha 
(* p < 0.05, as evaluated by Dunnett's test) 
 
